07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

EGEN-001: Phase Ib ongoing

An independent DMSB recommended continuation to the fourth and last cohort of the open-label, U.S. Phase Ib OVATION trial evaluating intraperitoneal GEN-1 with standard neoadjuvant chemotherapy based on safety data from the first 3 cohorts...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Company News

Celsion, Zhejiang Hisun Pharmaceutical deal

Celsion and Hisun partnered to manufacture Celsion’s GEN-1 in China, including Hong Kong and Macau, with an option to expand to other countries. The companies will collaborate to obtain regulatory approval in China. GEN-1, an...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

EGEN-001: Additional Phase Ib data

Data from 6 patients with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer in the first 2 cohorts of the open-label, U.S. Phase Ib OVATION Study showed that once-weekly intraperitoneal GEN-1 for 8...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Clinical News

EGEN-001: Phase Ib data

Top-line data from the first 3 patients with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer in the open-label, U.S. Phase Ib OVATION Study showed that once-weekly intraperitoneal GEN-1 for 8 weeks plus...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

EGEN-001: Phase Ib started

Celsion began the open-label, dose-escalation, U.S. Phase Ib OVATION Study to evaluate intraperitoneal GEN-1 with standard neoadjuvant chemotherapy in 15 patients. Celsion Corp. (NASDAQ:CLSN), Lawrenceville, N.J.   Product: EGEN-001, GEN-1   Business: Cancer   Molecular...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

EGEN-001: Phase Ib data

Data from 14 evaluable patients with platinum-resistant, persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in an open-label, U.S. Phase Ib trial showed that once-weekly intraperitoneal 24 and 36 mg/m 2 GEN-1...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Celsion, Egen deal

Celsion will acquire fellow cancer company Egen in a cash and stock deal worth up to $44.4 million. Egen will receive an upfront payment of $3.4 million in cash and $10.6 million in Celsion stock,...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Clinical News

EGEN-001: Phase I started

Egen said the Gynecologic Oncology Group (GOG) began an open-label, dose-escalation, U.S. Phase I trial to evaluate 18-36 mg/m 2 intraperitoneal EGEN-001 weekly plus IV pegylated liposomal doxorubicin monthly in a 4-week cycle in 18...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Clinical News

EGEN-001: Phase II started

Egen said the Gynecologic Oncology Group (GOG) began an open-label Phase II trial in 56 patients to evaluate weekly intraperitoneal EGEN-001 in a 4-week cycle. Egen Inc. , Huntsville, Ala.   Product: EGEN-001   Business:...
07:00 , Aug 19, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Liver cancer IL-12; granulocyte macrophage colony-stimulating factor (CSF2; GM-CSF); pigment epithelium derived factor (SERPINF1; PEDF); endostatin (ED) A study in woodchucks suggests that a...